Mylan Races To Launch Generic Norvasc

Law360, New York (March 23, 2007, 12:00 AM EDT) -- Just a day after a court ruled its rival’s patent invalid, Mylan Laboratories has rushed to launch a generic version of Pfizer Inc’s blockbuster drug Norvasc.

With no time wasted, Mylan launched three strengths of its amlodipine besylate tablets Friday and triggered its 180-day exclusivity.

The pharmaceutical company was the first generic drug maker to file an application for a cheap version of Pfizer’s popular blood pressure drug.

Although it lost its patent challenge against Pfizer some months ago, a second attempt to challenge the patent...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.